Upstream Process Development
Each step in an upstream process impacts the quality, purity and quantity of the manufactured protein. At AGC Biologics, we have developed over 80 mammalian, bacteria and yeast based processes in the last decade, giving us the insight necessary to identify and optimize upstream parameters that are critical for achieving a high-quality, cost-effective biomanufacturing process.
Our process transfer platform is well-substantiated and designed to scale-up directly, from bench-scale to final manufacturing scale, accelerating your development timelines. Utilizing our proprietary CHEF1™ expression platform, development timelines can be optimized further.
Our approach is flexible, based upon our clients’ needs. We can develop bioprocesses “from scratch” for customers with no existing upstream process, or we can redesign and optimize an existing process.
In addition, our development team is experienced with fast and effective technology transfer to establish proven cell culture and microbial fermentation processes. This ensures that you receive a seamless route to scale-up and cGMP manufacture.
Our upstream mammalian and microbial development capabilities include:
- Reliable transfer, verification and optimization of clients’ bioreactor process
- Scale-down fed-batch and perfusion production models
- Platform bioreactor processes for a variety of mammalian and microbial expression platforms
- Extensive experience with multiple mammalian cell types, including CHO DG44, CHOK1, HEK293, NS0 and PerC6
- Broad expertise with multiple microbial expression systems, including E. coli, Pseudomonas, Pichia and Saccharomyces cerevisiae
- Inclusion bodies, soluble intracellular and secreted to periplasm
- High cell density and titer optimization with multiple host cells (mammalian, bacteria and yeast)
- Extensive experience screening media and feeds
- Bench-scale process characterization and validation